Continuing Education Activity

Agoraphobia is characterized by anxiety or fear arising from thoughts that escape may be difficult or help may be unavailable in certain situations. This fear often centers on the possibility of experiencing panic-like symptoms or other embarrassing or incapacitating episodes. Individuals with agoraphobia tend to avoid these situations or require a companion for support. Severe cases can result in individuals becoming homebound and dependent on others, increasing the risk of depression.

Although agoraphobia and panic disorder are now separate diagnoses, they often co-occur. Treatment options include cognitive-behavioral therapy and pharmacotherapy, which can effectively reduce symptoms and improve quality of life. This activity reviews the diagnostic criteria and key characteristics of agoraphobia, highlighting the crucial role of the interprofessional team in the assessment and management of the condition.

Objectives:

• Identify the diagnostic criteria for agoraphobia as outlined in the DSM-5-TR, including the key characteristics and symptoms.
• Implement evidence-based interventions, including cognitive-behavioral therapy and pharmacotherapy, tailored to the patient’s needs.
• Assess the severity of agoraphobia symptoms and their impact on functional status and quality of life.
• Collaborate with interprofessional healthcare teams, including mental health specialists, primary care providers, and social workers, to optimize patient care.

Introduction

Agoraphobia is characterized by anxiety or fear in various situations arising from thoughts that escape may be difficult or help may not be readily available in certain situations. This fear often centers on the possibility of experiencing panic-like symptoms or other embarrassing or incapacitating episodes. Individuals with agoraphobia tend to avoid these situations or require a companion for support.[1] In severe cases of agoraphobia, individuals may become homebound or dependent on others for basic needs, which increases the risk of depression.

In previous editions of the Diagnostic and Statistical Manual of Mental Disorders (DSM), agoraphobia was combined with panic disorder.[2] Please see StatPearls' companion resource, "Panic Disorder," for more information. However, in the DSM, 5th ed., Text Revision (DSM-5-TR), agoraphobia and panic disorder are no longer linked, and agoraphobia is diagnosed independently of panic disorder. This change reflects research indicating that many individuals with agoraphobia do not experience panic disorder. Nonetheless, the DSM-5-TR notes that approximately 90% of individuals with agoraphobia have comorbid mental health conditions, such as other anxiety disorders, depressive disorders, posttraumatic stress disorder, or alcohol use disorder. Additionally, about 15% of individuals with agoraphobia report experiencing suicidal thoughts or behaviors.

Agoraphobia is diagnosed according to DSM-5-TR criteria when an individual experiences marked fear or anxiety about at least 2 of the following 5 situations—using public transportation, being in open spaces, being in enclosed spaces, standing in line or being in a crowd, or being outside the home alone. These situations almost always trigger disproportionate fear or anxiety, leading the individual to actively avoid them and resulting in clinically significant distress or functional impairment. This fear or anxiety cannot be attributed to a realistic threat, sociocultural factors, or substance use or withdrawal.[3] Symptoms must persist for at least 6 months to confirm the diagnosis of agoraphobia.

Etiology

The etiology of agoraphobia remains unclear, with limited studies focusing on it as a distinct condition. Older research suggests genetic factors may play a significant role, with heritability estimates ranging from 48% to 61%.[4] However, a study involving 3014 participants found that while a family history of panic disorder was associated with panic disorder with agoraphobia in offspring, agoraphobia without panic disorder did not show a familial association.[5]

Proposed contributing factors to the development of agoraphobia include adverse childhood events, such as a lack of parental warmth, parental overprotectiveness, childhood fears or night terrors, early-life experiences of grief or bereavement, and an unhappy or traumatic childhood.[6][7]

Personality traits associated with agoraphobia include neuroticism,[8] low extroversion,[9][10] anxiety sensitivity (the belief that physical symptoms of anxiety are dangerous),[11] and avoidant or dependent traits.[12] 

Epidemiology

The lifetime prevalence of anxiety disorders is approximately 34%, with specific rates including generalized anxiety disorder (6.2%), panic disorder (5.2%), agoraphobia (2.6%), social phobia (13.0%), specific phobia (13.8%), separation anxiety disorder (6.6%), posttraumatic stress disorder (8.0%), and obsessive-compulsive disorder (2.7%).[13][1] Estimates of agoraphobia prevalence vary, as it was only recently recognized as a distinct disorder separate from panic disorder. The 12-month prevalence of agoraphobia is estimated at 1.7%, with the highest rate observed in the 13 to 17 age group (2.0%), and a decline to 0.4% in individuals aged 65 and older.[13] 

A recent study reported a lifetime prevalence of agoraphobia at 0.9% in men and 2.0% in women.[14] Significant comorbidity was observed with other mental disorders, including major depressive disorder (12%), panic disorder (26%), specific phobia (5%), social phobia (4%), generalized anxiety disorder (7%), obsessive-compulsive disorder (4%), and posttraumatic stress disorder (2%).[14] 

Pathophysiology

A functional magnetic resonance imaging study examined the effects of anticipating and perceiving agoraphobia-specific stimuli. The study revealed stronger activations in the bilateral ventral striatum and left insula during the anticipation of agoraphobia-specific images in patients compared to controls, suggesting that these areas may serve as central neurofunctional correlates of agoraphobia.[15] This may indicate a neural correlate for anticipatory anxiety, potentially linked to increased attention to internal panic symptoms and heightened hypervigilance.[15] 

Based on the conceptual model of agoraphobia as a visuo-vestibular-spatial disorder involving the vestibular network, including the insula and limbic cortex, the authors of a case report investigated the neural correlates of agoraphobia in a patient who developed the condition following surgical removal of a parietal glioma. The authors provided further evidence that extensive post-surgery reorganization within the vestibular network, indicated by changes in structural and functional connectivity across several network nodes, could explain the agoraphobic symptoms reported by this patient. Notably, the surgical lesion was primarily located within the visuospatial-emotional network, suggesting that, at least in part, the development of the agoraphobic symptoms may be due to the surgical disruption of this network component.[16]

A study involving 106 individuals (53 with agoraphobia and 53 without) navigating a virtual square with and without people found that those with agoraphobia exhibited reduced working memory, but only when active processing of spatial elements was required. This suggests difficulties in spatial tasks, particularly those that involve processing information simultaneously. Visuospatial working memory deficits were found to impact the relationship between agoraphobia and task performance.[17]

History and Physical

The Women's Preventive Services Initiative and the United States Preventive Services Task Force both recommend routine screening for anxiety disorders. Screening measures such as the generalized anxiety disorder-7 (GAD-7), which takes less than 5 minutes, can help identify individuals with anxiety disorders that might otherwise go undetected.[2][18]

As anxious avoidance of situations is common across various mental disorders, the Oxford-Agoraphobic Avoidance Scale (a brief questionnaire) was developed as a self-report measure to assess agoraphobia symptoms.[19] The scale includes items related to everyday activities of increasing difficulty and in various locations. Each item is rated on 2 separate scales, as mentioned below.

• First, the participant provides an avoidance rating to indicate whether they believe they could complete the activity at that moment. The activity items include standing outside their home alone for 5 minutes, walking down a quiet street alone, walking down a busy street with someone they know, traveling alone on a bus for several stops, sitting alone in the waiting room of a general practitioner or health center for 5 minutes, purchasing an item from a shop assistant, going to a shopping center alone for 15 minutes, and sitting alone in a café for 10 minutes.

• Second, the participant rates how anxious they would feel performing each task on a scale from 0 (no distress) to 10 (extreme distress). Higher scores for avoidance and distress are associated with more severe agoraphobia symptoms.[19]

Other psychiatric and medical conditions should always be considered when assessing an individual with suspected agoraphobia. Anxiety disorders, mood disorders, and substance use disorders are commonly comorbid with agoraphobia. Assessing suicide risk is crucial, as individuals with agoraphobia are at an increased risk of suicidal thoughts or behaviors.

Evaluation

No laboratory, radiographic, or other tests are required to evaluate agoraphobia.

Treatment / Management

Panic disorder and agoraphobia are distinct diagnoses, but their treatment approaches are similar, and the 2 disorders may occur together.

The first step is to assess the severity of the condition at the time of the patient's presentation, which typically reflects the level of impairment or distress caused by agoraphobia or panic disorder. For patients with mild-to-moderate forms of these disorders, both psychotherapy and pharmacotherapy are effective options for symptom management. Studies generally conclude that cognitive-behavioral therapy effectively targets and alleviates primary symptoms, reduces other anxiety symptoms, and improves the patient's overall quality of life.[20]

For patients with more severe agoraphobia or those who prefer pharmacotherapy over psychotherapy, several effective medication options are available for medication management. Selective serotonin reuptake inhibitors (SSRIs) are typically considered first-line treatment, with therapeutic doses similar to those used for depression.[21] Serotonin-norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants, and benzodiazepines are also effective alternatives to SSRIs in treating panic disorder and agoraphobia.[22][23] 

Benzodiazepines are generally not preferred, especially for long-term use or as monotherapy, due to their potential for abuse and higher risk of adverse effects, such as sedation, impaired memory, cognitive dysfunction, and an increased risk of falls.[24] SSRIs are typically preferred over these alternatives because of their more favorable side effect profile, affordability, availability, lower potential for abuse, and better overall tolerability.[25][26][27]

Although most SSRIs are relatively comparable in achieving remission of agoraphobia symptoms, sertraline and escitalopram have been associated with higher rates of remission and a lower risk of adverse events.[28] Additionally, data suggest that combining cognitive-behavioral therapy with pharmacotherapy may offer the most effective symptomatic management for agoraphobia and panic disorder.[29]

Differential Diagnosis

According to the DSM-5-TR, the differential diagnoses for agoraphobia include the below-mentioned conditions.

• Specific phobia, situational type: The diagnosis for this condition should be considered when fear, anxiety, or avoidance is triggered by just 1 specific situation. Agoraphobia is diagnosed when 2 or more agoraphobic situations provoke excessive fear or anxiety. A key distinguishing feature is the content of the individual's thoughts. If the situation is feared for reasons other than the possibility of panic symptoms or other incapacitating or embarrassing symptoms, a diagnosis of a specific phobia may be more appropriate.

• Separation anxiety disorder: This condition can be differentiated from agoraphobia when the fear or anxiety arises from detachment from loved ones or the home environment rather than from being in the feared situations themselves.

• Social anxiety: This condition involves the fear of being negatively judged in public situations rather than the fear of being in the situations themselves.

• Panic disorder: This condition is the appropriate diagnosis when panic symptoms occur independently of agoraphobic situations.

• Acute stress disorder and posttraumatic stress disorder: These conditions are characterized by fear, anxiety, or avoidance related to a past traumatic event or reminders of trauma.

• Major depressive disorder: This condition should be considered if the patient reports avoiding leaving home due to symptoms such as anhedonia, apathy, loss of energy, insomnia, or low self-esteem.

Agoraphobia should not be diagnosed if the fears stem from underlying medical conditions, and the behavioral modifications are made to avoid the consequences of these conditions, such as the fear of losing consciousness in public due to cardiovascular pathology or the fear of developing diarrhea in someone with inflammatory bowel disease.

Pertinent Studies and Ongoing Trials

The National Institutes of Mental Health (NIMH) is currently conducting the Family Study of Health and Behavior, which aims to examine how mood disorders, anxiety disorders, and migraine headaches run in families. The study focuses on genetic and environmental factors contributing to these conditions.

The NIMH is also conducting the Pediatric Mood and Anxiety Research study, which aims to understand how the brain functions in children and adolescents aged 8 to 17 with anxiety or depression. Participants in the study engage in brain imaging and computer-based tasks designed to assess problem-solving and memory.

Prognosis

The DSM-5-TR characterizes the typical course of agoraphobia as "persistent and chronic," with complete remission being rare without treatment or intervention.[30] Rates of remission are lower in individuals with more severe agoraphobia. The likelihood of a favorable prognosis is further diminished when comorbid conditions such as anxiety disorders, depression, personality disorders, or substance use disorders are present.

Complications

Agoraphobia is associated with significant distress and life impairment, including decreased work productivity, increased disability days, and a reduced likelihood of marriage when it manifests early. In severe cases, individuals may become completely home-bound and reliant on others for basic needs. This can lead to self-medication with alcohol and sedative medications.

The DSM-5-TR states that remission rates for agoraphobia without treatment are low (10%). In addition, it is also associated with an increased risk of developing comorbid conditions such as major depressive disorder, persistent depressive disorder, and substance use disorders. Additionally, individuals with agoraphobia are at a higher risk of experiencing suicidal thoughts or behaviors.

Deterrence and Patient Education

Effective management strategies for agoraphobia include early identification of symptoms, prompt intervention, access to resources and mental health professionals, open communication with patients, and appropriate treatment through psychotherapy or pharmacotherapy. 

Individuals and their family members should be educated that agoraphobia is an anxiety disorder characterized by fear and avoidance of situations that may lead to feelings of being trapped, helpless, embarrassed, or panicked. Education should include information about treatment options, such as cognitive behavioral therapy and medications. Although agoraphobia can lead to feelings of fear and isolation, symptoms can be effectively managed with appropriate treatment.

Pearls and Other Issues

Key facts to keep in mind regarding agoraphobia include:

• Anxiety disorders, including agoraphobia, are often overlooked by healthcare providers.
• About 15% of individuals with agoraphobia experience suicidal thoughts or behavior.
• Agoraphobia is associated with significant impairment in multiple areas, including relationships, role functioning, and work productivity.
• Panic disorder, other anxiety disorders, depression, and substance use disorders are frequently comorbid with agoraphobia. 

Enhancing Healthcare Team Outcomes

Patients with agoraphobia often experience significant impairment and disability. Early identification and management are crucial to reducing morbidity and mortality. Effective care requires a collaborative, multidisciplinary approach among healthcare professionals to deliver patient-centered treatment and achieve improved outcomes. Primary care physicians, psychiatrists, psychologists, advanced practitioners, social workers, nurses, pharmacists, occupational therapists, physical therapists, and other healthcare professionals should be equipped with the knowledge and skills to recognize, diagnose, and manage agoraphobia effectively. Educating patients and caregivers is crucial for preventing the morbidity associated with agoraphobia.

A strategic approach is essential, incorporating evidence-based practices to optimize treatment plans while minimizing adverse effects. Ethical considerations should underpin decision-making, emphasizing informed consent and respecting patient autonomy in treatment choices. Each healthcare professional must understand their role and contribute their specialized expertise to the care plan, promoting a cohesive and effective multidisciplinary approach.

Effective communication among interprofessional healthcare providers is essential for seamless information exchange and collaborative decision-making among team members. Coordinated care is crucial to managing the patient’s journey from diagnosis to treatment and follow-up, thereby minimizing errors and enhancing patient safety. By embracing principles of skill, strategy, ethics, responsibilities, interprofessional communication, and care coordination, healthcare professionals can provide patient-centered care, ultimately improving outcomes and enhancing team performance in managing agoraphobia.

Review Questions

• Access free multiple choice questions on this topic.
• Click here for a simplified version.
• Comment on this article.

References

1.

Roest AM, de Vries YA, Lim CCW, Wittchen HU, Stein DJ, Adamowski T, Al-Hamzawi A, Bromet EJ, Viana MC, de Girolamo G, Demyttenaere K, Florescu S, Gureje O, Haro JM, Hu C, Karam EG, Caldas-de-Almeida JM, Kawakami N, Lépine JP, Levinson D, Medina-Mora ME, Navarro-Mateu F, O'Neill S, Piazza M, Posada-Villa JA, Slade T, Torres Y, Kessler RC, Scott KM, de Jonge P., WHO World Mental Health Survey Collaborators. A comparison of DSM-5 and DSM-IV agoraphobia in the World Mental Health Surveys. Depress Anxiety. 2019 Jun;36(6):499-510. [PMC free article: PMC6548607] [PubMed: 30726581]

2.

Szuhany KL, Simon NM. Anxiety Disorders: A Review. JAMA. 2022 Dec 27;328(24):2431-2445. [PubMed: 36573969]

3.

Asmundson GJ, Taylor S, Smits JA. Panic disorder and agoraphobia: an overview and commentary on DSM-5 changes. Depress Anxiety. 2014 Jun;31(6):480-6. [PubMed: 24865357]

4.

Noyes R, Crowe RR, Harris EL, Hamra BJ, McChesney CM, Chaudhry DR. Relationship between panic disorder and agoraphobia. A family study. Arch Gen Psychiatry. 1986 Mar;43(3):227-32. [PubMed: 3954542]

5.

Nocon A, Wittchen HU, Beesdo K, Brückl T, Hofler M, Pfister H, Zimmermann P, Lieb R. Differential familial liability of panic disorder and agoraphobia. Depress Anxiety. 2008;25(5):422-34. [PubMed: 18023003]

6.

Remmerswaal KCP, Ten Have M, de Graaf R, van Balkom AJLM, Penninx BWJH, Batelaan NM. Risk factors of chronic course of anxiety and depressive disorders: a 3-year longitudinal study in the general population. Soc Psychiatry Psychiatr Epidemiol. 2024 Sep;59(9):1607-1615. [PubMed: 38015237]

7.

Wittchen HU, Gloster AT, Beesdo-Baum K, Fava GA, Craske MG. Agoraphobia: a review of the diagnostic classificatory position and criteria. Depress Anxiety. 2010 Feb;27(2):113-33. [PubMed: 20143426]

8.

Prince EJ, Siegel DJ, Carroll CP, Sher KJ, Bienvenu OJ. A longitudinal study of personality traits, anxiety, and depressive disorders in young adults. Anxiety Stress Coping. 2021 May;34(3):299-307. [PMC free article: PMC8068574] [PubMed: 33190525]

9.

Bienvenu OJ, Brown C, Samuels JF, Liang KY, Costa PT, Eaton WW, Nestadt G. Normal personality traits and comorbidity among phobic, panic and major depressive disorders. Psychiatry Res. 2001 May 10;102(1):73-85. [PubMed: 11368842]

10.

Bienvenu OJ, Samuels JF, Costa PT, Reti IM, Eaton WW, Nestadt G. Anxiety and depressive disorders and the five-factor model of personality: a higher- and lower-order personality trait investigation in a community sample. Depress Anxiety. 2004;20(2):92-7. [PubMed: 15390211]

11.

Hayward C, Wilson KA. Anxiety sensitivity: a missing piece to the agoraphobia-without-panic puzzle. Behav Modif. 2007 Mar;31(2):162-73. [PubMed: 17307933]

12.

Bienvenu OJ, Stein MB, Samuels JF, Onyike CU, Eaton WW, Nestadt G. Personality disorder traits as predictors of subsequent first-onset panic disorder or agoraphobia. Compr Psychiatry. 2009 May-Jun;50(3):209-14. [PMC free article: PMC2691589] [PubMed: 19374963]

13.

Kessler RC, Petukhova M, Sampson NA, Zaslavsky AM, Wittchen H -U. Twelve-month and lifetime prevalence and lifetime morbid risk of anxiety and mood disorders in the United States. Int J Methods Psychiatr Res. 2012 Sep;21(3):169-84. [PMC free article: PMC4005415] [PubMed: 22865617]

14.

Preti A, Piras M, Cossu G, Pintus E, Pintus M, Kalcev G, Cabras F, Moro MF, Romano F, Balestrieri M, Caraci F, Dell'Osso L, Sciascio GD, Drago F, Hardoy MC, Roncone R, Faravelli C, Musu M, Finco G, Nardi AE, Carta MG. The Burden of Agoraphobia in Worsening Quality of Life in a Community Survey in Italy. Psychiatry Investig. 2021 Apr;18(4):277-283. [PMC free article: PMC8103017] [PubMed: 33849246]

15.

Wittmann A, Schlagenhauf F, Guhn A, Lueken U, Gaehlsdorf C, Stoy M, Bermpohl F, Fydrich T, Pfleiderer B, Bruhn H, Gerlach AL, Kircher T, Straube B, Wittchen HU, Arolt V, Heinz A, Ströhle A. Anticipating agoraphobic situations: the neural correlates of panic disorder with agoraphobia. Psychol Med. 2014 Aug;44(11):2385-96. [PubMed: 24398049]

16.

Indovina I, Cacciola A, Delle Monache S, Milardi D, Lacquaniti F, Toschi N, Cochereau J, Bosco G. A case report of agoraphobia following right parietal lobe surgery: changes in functional and structural connectivities of the multimodal vestibular network. Front Neurol. 2023;14:1163005. [PMC free article: PMC10213528] [PubMed: 37251237]

17.

Zucchelli MM, Piccardi L, Nori R. The Fear to Move in a Crowded Environment. Poor Spatial Memory Related to Agoraphobic Disorder. Brain Sci. 2021 Jun 16;11(6) [PMC free article: PMC8235653] [PubMed: 34208661]

18.

Spitzer RL, Kroenke K, Williams JB, Löwe B. A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med. 2006 May 22;166(10):1092-7. [PubMed: 16717171]

19.

Lambe S, Bird JC, Loe BS, Rosebrock L, Kabir T, Petit A, Mulhall S, Jenner L, Aynsworth C, Murphy E, Jones J, Powling R, Chapman K, Dudley R, Morrison A, Regan EO, Yu LM, Clark D, Waite F, Freeman D. The Oxford Agoraphobic Avoidance Scale. Psychol Med. 2023 Mar;53(4):1233-1243. [PMC free article: PMC10009387] [PubMed: 37010211]

20.

Carpenter JK, Andrews LA, Witcraft SM, Powers MB, Smits JAJ, Hofmann SG. Cognitive behavioral therapy for anxiety and related disorders: A meta-analysis of randomized placebo-controlled trials. Depress Anxiety. 2018 Jun;35(6):502-514. [PMC free article: PMC5992015] [PubMed: 29451967]

21.

Otto MW, Tuby KS, Gould RA, McLean RY, Pollack MH. An effect-size analysis of the relative efficacy and tolerability of serotonin selective reuptake inhibitors for panic disorder. Am J Psychiatry. 2001 Dec;158(12):1989-92. [PubMed: 11729014]

22.

Plag J, Petzold MB, Gechter J, Liebscher C, Ströhle A. Patients' characteristics and their influence on course of fear during agoraphobic symptom provocation: may SS(N)RI treatment compensate unfavorable individual preconditions? Nord J Psychiatry. 2018 Jul;72(5):325-335. [PubMed: 29644923]

23.

Imai H, Tajika A, Chen P, Pompoli A, Furukawa TA. Psychological therapies versus pharmacological interventions for panic disorder with or without agoraphobia in adults. Cochrane Database Syst Rev. 2016 Oct 12;10(10):CD011170. [PMC free article: PMC6457876] [PubMed: 27730622]

24.

Bandelow B. Current and Novel Psychopharmacological Drugs for Anxiety Disorders. Adv Exp Med Biol. 2020;1191:347-365. [PubMed: 32002937]

25.

Bakker A, van Balkom AJ, Spinhoven P. SSRIs vs. TCAs in the treatment of panic disorder: a meta-analysis. Acta Psychiatr Scand. 2002 Sep;106(3):163-7. [PubMed: 12197851]

26.

Wilkinson G, Balestrieri M, Ruggeri M, Bellantuono C. Meta-analysis of double-blind placebo-controlled trials of antidepressants and benzodiazepines for patients with panic disorders. Psychol Med. 1991 Nov;21(4):991-8. [PubMed: 1685792]

27.

Pollack MH, Lepola U, Koponen H, Simon NM, Worthington JJ, Emilien G, Tzanis E, Salinas E, Whitaker T, Gao B. A double-blind study of the efficacy of venlafaxine extended-release, paroxetine, and placebo in the treatment of panic disorder. Depress Anxiety. 2007;24(1):1-14. [PubMed: 16894619]

28.

Chawla N, Anothaisintawee T, Charoenrungrueangchai K, Thaipisuttikul P, McKay GJ, Attia J, Thakkinstian A. Drug treatment for panic disorder with or without agoraphobia: systematic review and network meta-analysis of randomised controlled trials. BMJ. 2022 Jan 19;376:e066084. [PMC free article: PMC8767458] [PubMed: 35045991]

29.

Furukawa TA, Watanabe N, Churchill R. Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia. Cochrane Database Syst Rev. 2007 Jan 24;2007(1):CD004364. [PMC free article: PMC6823237] [PubMed: 17253502]

30.

Perugi G, Frare F, Toni C. Diagnosis and treatment of agoraphobia with panic disorder. CNS Drugs. 2007;21(9):741-64. [PubMed: 17696574]

Disclosure: Kripa Balaram declares no relevant financial relationships with ineligible companies.

Disclosure: Raman Marwaha declares no relevant financial relationships with ineligible companies.